Compare WHLR & BBLG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WHLR | BBLG |
|---|---|---|
| Founded | 2011 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Industrial Specialties |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5M | 1.2M |
| IPO Year | 2011 | 2014 |
| Metric | WHLR | BBLG |
|---|---|---|
| Price | $0.36 | $0.53 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 43.8K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.64 | 45.13 |
| EPS | ★ N/A | N/A |
| Revenue | $99,445,000.00 | ★ $1,070,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.21 | $0.54 |
| 52 Week High | $7.28 | $2.89 |
| Indicator | WHLR | BBLG |
|---|---|---|
| Relative Strength Index (RSI) | 43.07 | 26.39 |
| Support Level | $0.31 | N/A |
| Resistance Level | $1.54 | $1.35 |
| Average True Range (ATR) | 0.15 | 0.03 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 1.87 | 27.48 |
Wheeler Real Estate Investment Trust Inc is a self-managed commercial real estate investment company. It owns, leases, and operates income-producing retail properties with a primary focus on grocery-anchored centers. The company's properties include Alex City Marketplace in Alexander City, Alabama; Bryan Station in Lexington, Kentucky; Cardinal Plaza in Henderson, North Carolina; Clover Plaza in Clover, South Carolina; Cypress Shopping Center in Boiling Springs, South Carolina, and others.
Bone Biologics Corp a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that provides target specific control over bone regeneration. It is a clinical-stage entity. The production and marketing of its products and ongoing research and development activities are subject to extensive regulation by numerous governmental authorities in the United States.